Commit Biologics announces €5.5m seed financing extension investment by Korys to further develop its Bispecific Complement Engaging (BiCE™) platform
- Additional funding from new investor Korys, joining existing syndicate members Novo Holdings and Bioqube Ventures, brings total seed financing to €21.5m
- Funds will be used to further develop Commit’s BiCE platform and move towards drug candidate (DC) selection
- Eva Van Overmeire, Senior Investment Manager at Korys, also joins Commit’s Board of Directors
- Mikkel Wandahl Pedersen appointed as interim CEO
Aarhus, Denmark – 28 January 2025 – Commit Biologics (“Commit”), a pioneer in the activation of the complement system to treat cancer and autoimmune disease, today announces a €5.5m extension to its seed financing. The contribution from new investor Korys brings the total seed financing raised since Commit’s launch to €21.5m. Commit emerged from stealth last May, having raised €16m from Novo Holdings and Bioqube Ventures.